• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

DTX3L E3连接酶在聚ADP核糖聚合酶相关的DNA损伤位点靶向p53进行降解。

DTX3L E3 ligase targets p53 for degradation at poly ADP-ribose polymerase-associated DNA damage sites.

作者信息

Yan Qingsheng, Ding Jingyi, Khan Sumbul Jawed, Lawton Lee N, Shipp Margaret A

机构信息

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.

出版信息

iScience. 2023 Mar 17;26(4):106444. doi: 10.1016/j.isci.2023.106444. eCollection 2023 Apr 21.

DOI:10.1016/j.isci.2023.106444
PMID:37096048
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10122052/
Abstract

P53 is a master transcriptional regulator and effector of the DNA damage response (DDR) that localizes to DNA damage sites, in part, via an interaction with PARP1. However, the mechanisms that regulate p53 abundance and activity at PARP1-decorated DNA damage sites remain undefined. The PARP9 (BAL1) macrodomain-containing protein and its partner DTX3L (BBAP) E3 ligase are rapidly recruited to PARP1-PARylated DNA damage sites. During an initial DDR, we found that DTX3L rapidly colocalized with p53, polyubiquitylated its lysine-rich C-terminal domain, and targeted p53 for proteasomal degradation. DTX3L knockout significantly increased and prolonged p53 retention at PARP-decorated DNA damage sites. These findings reveal a non-redundant, PARP- and PARylation-dependent role for DTX3L in the spatiotemporal regulation of p53 during an initial DDR. Our studies suggest that targeted inhibition of DTX3L may augment the efficacy of certain DNA-damaging agents by increasing p53 abundance and activity.

摘要

P53是一种主要的转录调节因子,也是DNA损伤反应(DDR)的效应器,它部分通过与PARP1相互作用定位于DNA损伤位点。然而,在PARP1修饰的DNA损伤位点调节p53丰度和活性的机制仍不明确。含PARP9(BAL1)宏结构域的蛋白质及其伴侣DTX3L(BBAP)E3连接酶会迅速被招募到PARP1-聚腺苷酸化的DNA损伤位点。在初始DDR过程中,我们发现DTX3L迅速与p53共定位,使其富含赖氨酸的C末端结构域多聚泛素化,并将p53靶向蛋白酶体降解。DTX3L基因敲除显著增加并延长了p53在PARP修饰的DNA损伤位点的保留时间。这些发现揭示了DTX3L在初始DDR期间对p53的时空调节中具有非冗余的、PARP和聚腺苷酸化依赖性的作用。我们的研究表明,靶向抑制DTX3L可能通过增加p53的丰度和活性来增强某些DNA损伤剂的疗效。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6717/10122052/d273e59869c8/fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6717/10122052/d273e59869c8/fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6717/10122052/d273e59869c8/fx1.jpg

相似文献

1
DTX3L E3 ligase targets p53 for degradation at poly ADP-ribose polymerase-associated DNA damage sites.DTX3L E3连接酶在聚ADP核糖聚合酶相关的DNA损伤位点靶向p53进行降解。
iScience. 2023 Mar 17;26(4):106444. doi: 10.1016/j.isci.2023.106444. eCollection 2023 Apr 21.
2
BAL1 and its partner E3 ligase, BBAP, link Poly(ADP-ribose) activation, ubiquitylation, and double-strand DNA repair independent of ATM, MDC1, and RNF8.BAL1 及其伙伴 E3 连接酶 BBAP 将 Poly(ADP-ribose) 的激活、泛素化和双链 DNA 修复与 ATM、MDC1 和 RNF8 联系起来。
Mol Cell Biol. 2013 Feb;33(4):845-57. doi: 10.1128/MCB.00990-12. Epub 2012 Dec 10.
3
Reconstitution of the DTX3L-PARP9 complex reveals determinants for high-affinity heterodimerization and multimeric assembly.DTX3L-PARP9 复合物的重建揭示了高亲和力异二聚体形成和多聚体组装的决定因素。
Biochem J. 2022 Feb 11;479(3):289-304. doi: 10.1042/BCJ20210722.
4
Ubiquitin Modification by the E3 Ligase/ADP-Ribosyltransferase Dtx3L/Parp9.E3 连接酶/ADP-核糖基转移酶 Dtx3L/Parp9 介导的泛素修饰
Mol Cell. 2017 May 18;66(4):503-516.e5. doi: 10.1016/j.molcel.2017.04.028.
5
DTX3L and ARTD9 inhibit IRF1 expression and mediate in cooperation with ARTD8 survival and proliferation of metastatic prostate cancer cells.DTX3L和ARTD9抑制IRF1表达,并与ARTD8协同介导转移性前列腺癌细胞的存活和增殖。
Mol Cancer. 2014 May 27;13:125. doi: 10.1186/1476-4598-13-125.
6
KH-like Domains in PARP9/DTX3L and PARP14 Coordinate Protein-Protein Interactions to Promote Cancer Cell Survival.PARP9/DTX3L 和 PARP14 中的 KH 结构域协调蛋白-蛋白相互作用,促进癌细胞存活。
J Mol Biol. 2024 Feb 15;436(4):168434. doi: 10.1016/j.jmb.2023.168434. Epub 2024 Jan 3.
7
Erratum: DTX3L E3 ligase targets p53 for degradation at poly ADP-ribose polymerase-associated DNA damage sites.勘误:DTX3L E3 连接酶在聚 ADP 核糖聚合酶相关的 DNA 损伤位点靶向 p53 进行降解。
iScience. 2024 Jul 2;27(7):110386. doi: 10.1016/j.isci.2024.110386. eCollection 2024 Jul 19.
8
The SARS-CoV-2 Nsp3 macrodomain reverses PARP9/DTX3L-dependent ADP-ribosylation induced by interferon signaling.SARS-CoV-2 Nsp3 宏结构域逆转干扰素信号诱导的 PARP9/DTX3L 依赖性 ADP-核糖基化。
J Biol Chem. 2021 Sep;297(3):101041. doi: 10.1016/j.jbc.2021.101041. Epub 2021 Aug 4.
9
Phosphatase 1 Nuclear Targeting Subunit Mediates Recruitment and Function of Poly (ADP-Ribose) Polymerase 1 in DNA Repair.磷酸酶 1 核靶向亚基介导聚(ADP-核糖)聚合酶 1 在 DNA 修复中的募集和功能。
Cancer Res. 2019 May 15;79(10):2526-2535. doi: 10.1158/0008-5472.CAN-18-1673. Epub 2019 Feb 7.
10
MORC2 regulates DNA damage response through a PARP1-dependent pathway.MORC2 通过依赖 PARP1 的途径调节 DNA 损伤反应。
Nucleic Acids Res. 2019 Sep 19;47(16):8502-8520. doi: 10.1093/nar/gkz545.

引用本文的文献

1
The E3 ubiquitin ligase DTX3L and the deubiquitinase USP28 fine-tune DNA repair through mutual regulation of their protein levels.E3泛素连接酶DTX3L和去泛素化酶USP28通过相互调节其蛋白质水平来微调DNA修复。
iScience. 2025 Jun 24;28(8):112990. doi: 10.1016/j.isci.2025.112990. eCollection 2025 Aug 15.
2
Parp7 generates an ADP-ribosyl degron that controls negative feedback of androgen signaling.聚(ADP-核糖)聚合酶7生成一种ADP-核糖基降解子,该降解子控制雄激素信号的负反馈。
EMBO J. 2025 Jul 18. doi: 10.1038/s44318-025-00510-4.
3
PARP9-PARP13-PARP14 axis tunes colorectal cancer response to radiotherapy.

本文引用的文献

1
Targeting DNA damage response pathways in cancer.靶向癌症中的DNA损伤反应通路。
Nat Rev Cancer. 2023 Feb;23(2):78-94. doi: 10.1038/s41568-022-00535-5. Epub 2022 Dec 5.
2
Activities and binding partners of E3 ubiquitin ligase DTX3L and its roles in cancer.E3 泛素连接酶 DTX3L 的活性及其结合伙伴及其在癌症中的作用。
Biochem Soc Trans. 2022 Dec 16;50(6):1683-1692. doi: 10.1042/BST20220501.
3
Drugging p53 in cancer: one protein, many targets.在癌症中靶向 p53:一种蛋白,多个靶点。
PARP9-PARP13-PARP14轴调节结直肠癌对放疗的反应。
J Exp Clin Cancer Res. 2025 Jul 11;44(1):199. doi: 10.1186/s13046-025-03439-y.
4
Deciphering the potential role of post-translational modifications of histones in gastrointestinal cancers: a proteomics-based review with therapeutic challenges and opportunities.解读组蛋白翻译后修饰在胃肠道癌症中的潜在作用:基于蛋白质组学的综述及治疗挑战与机遇
Front Oncol. 2024 Oct 21;14:1481426. doi: 10.3389/fonc.2024.1481426. eCollection 2024.
5
PARP14 and PARP9/DTX3L regulate interferon-induced ADP-ribosylation.PARP14 和 PARP9/DTX3L 调节干扰素诱导的 ADP-ribosylation。
EMBO J. 2024 Jul;43(14):2929-2953. doi: 10.1038/s44318-024-00126-0. Epub 2024 Jun 4.
6
Deltex family E3 ligases specifically ubiquitinate the terminal ADP-ribose of poly(ADP-ribosyl)ation.Deltex 家族 E3 连接酶特异性泛素化聚(ADP-核糖)化的末端 ADP-核糖。
Biochem Biophys Res Commun. 2024 Aug 6;720:150101. doi: 10.1016/j.bbrc.2024.150101. Epub 2024 May 11.
7
PARP14 is a PARP with both ADP-ribosyl transferase and hydrolase activities.PARP14 是一种具有 ADP-ribosyl 转移酶和水解酶活性的 PARP。
Sci Adv. 2023 Sep 15;9(37):eadi2687. doi: 10.1126/sciadv.adi2687. Epub 2023 Sep 13.
8
The DTX Protein Family: .DTX 蛋白家族:概述。
Cells. 2023 Jun 21;12(13):1680. doi: 10.3390/cells12131680.
Nat Rev Drug Discov. 2023 Feb;22(2):127-144. doi: 10.1038/s41573-022-00571-8. Epub 2022 Oct 10.
4
DELTEX E3 ligases ubiquitylate ADP-ribosyl modification on protein substrates.DELTEX E3 连接酶使蛋白质底物上的 ADP 核糖基修饰发生泛素化。
Sci Adv. 2022 Oct 7;8(40):eadd4253. doi: 10.1126/sciadv.add4253. Epub 2022 Oct 5.
5
Poly(ADP-Ribose) Polymerase Inhibitors in the Management of Ovarian Cancer: ASCO Guideline Rapid Recommendation Update.聚(ADP - 核糖)聚合酶抑制剂在卵巢癌治疗中的应用:美国临床肿瘤学会指南快速推荐更新
J Clin Oncol. 2022 Nov 20;40(33):3878-3881. doi: 10.1200/JCO.22.01934. Epub 2022 Sep 23.
6
The expanding universe of PARP1-mediated molecular and therapeutic mechanisms.PARP1 介导的分子和治疗机制的不断扩展的领域。
Mol Cell. 2022 Jun 16;82(12):2315-2334. doi: 10.1016/j.molcel.2022.02.021. Epub 2022 Mar 9.
7
Rapid recruitment of p53 to DNA damage sites directs DNA repair choice and integrity.p53 快速募集到 DNA 损伤位点指导 DNA 修复选择和完整性。
Proc Natl Acad Sci U S A. 2022 Mar 8;119(10):e2113233119. doi: 10.1073/pnas.2113233119. Epub 2022 Mar 2.
8
It's Getting Complicated-A Fresh Look at p53-MDM2-ARF Triangle in Tumorigenesis and Cancer Therapy.情况愈发复杂——重新审视肿瘤发生与癌症治疗中的p53-MDM2-ARF三角关系
Front Cell Dev Biol. 2022 Jan 26;10:818744. doi: 10.3389/fcell.2022.818744. eCollection 2022.
9
ADP-ribosyltransferases, an update on function and nomenclature.ADP-核糖基转移酶:功能和命名法的最新进展。
FEBS J. 2022 Dec;289(23):7399-7410. doi: 10.1111/febs.16142. Epub 2021 Sep 13.
10
Understanding and overcoming resistance to PARP inhibitors in cancer therapy.理解和克服癌症治疗中对 PARP 抑制剂的耐药性。
Nat Rev Clin Oncol. 2021 Dec;18(12):773-791. doi: 10.1038/s41571-021-00532-x. Epub 2021 Jul 20.